公开(公告)号：US20190062353A1

公开(公告)日：2019-02-28

申请号：US16174704

申请日：2018-10-30

申请人： UBE INDUSTRIES, LTD.

发明人： Noriaki IWASE ,  Shigeyuki KONO ,  Masayuki TANAKA ,  Masaaki MATOYAMA ,  Satoshi UMEZAKI ,  Yusuke SHIRAISHI ,  Masahiro KOJIMA ,  Hayato NISHIYAMA

IPC分类号： C07F7/10 ,  A61K31/695

摘要： Methods of producing a compound represented by formula (I) or a pharmacologically acceptable salt thereof include: wherein L1 is an optionally substituted C1-6 alkylene group or the like, L2 is a single bond or the like, L3 is a single bond or the like, R1, R2, and R3 are each independently an optionally substituted C1-4 alkyl group or the like, R4 is a hydrogen atom or the like, and R5 is a hydrogen atom or the like.

公开(公告)号：US20170313727A1

公开(公告)日：2017-11-02

申请号：US15522592

申请日：2015-10-30

申请人： UBE INDUSTRIES, LTD.

发明人： Yasuhiro AGA ,  Shigeru USHIYAMA ,  Noriaki IWASE ,  Shigeyuki KONO ,  Hidetoshi SUNAMOTO ,  Takashi MATSUSHITA ,  Sayaka OGI ,  Masayuki TANAKA ,  Masaaki MATOYAMA ,  Satoshi UMEZAKI ,  Yusuke SHIRAISHI ,  Kazuhiro ONUMA ,  Masahiro KOJIMA ,  Hayato NISHIYAMA ,  Tomio KIMURA

IPC分类号： C07F7/10

CPC分类号： C07F7/10 ,  A61K31/695 ,  Y02P20/55

摘要： Provided is a compound represented by formula (I) or a pharmacologically acceptable salt thereof: wherein L1 is an optionally substituted C1-6 alkylene group or the like, L2 is a single bond or the like, L3 is a single bond or the like, R1, R2, and R3 are each independently an optionally substituted C1-4 alkyl group or the like, R4 is a hydrogen atom or the like, and R5 is a hydrogen atom or the like.

公开(公告)号：US20140113907A1

公开(公告)日：2014-04-24

申请号：US14108029

申请日：2013-12-16

申请人： UBE INDUSTRIES, LTD.

发明人： Ryo IWAMURA ,  Masayuki TANAKA ,  Tetsushi KATSUBE ,  Manabu SHIGETOMI ,  Eiji OKANARI ,  Yasunori TOKUNAGA ,  Hiroshi FUJIWARA

IPC分类号： C07D417/14 ,  C07D409/14 ,  C07D213/74 ,  C07D405/14 ,  C07D401/14 ,  C07D417/12

摘要： The present invention provides a pyridylaminoacetic acid compound represented by the following formula (1): (wherein R1, R2, R3, Y and Z are as defined in the description and claims), or a pharmacologically acceptable salt thereof. Since the pyridylaminoacetic acid compound has EP2 agonistic action, it is useful as a therapeutic or prophylactic drug for respiratory diseases such as asthma or chronic obstructive pulmonary disease.

摘要翻译： 本发明提供由下式（1）表示的吡啶基氨基乙酸化合物或其药理学上可接受的盐，其中R1，R2，R3，Y和Z如说明书和权利要求中所定义。 由于吡啶基氨基乙酸化合物具有EP2激动作用，因此可用作呼吸系统疾病如哮喘或慢性阻塞性肺疾病的治疗或预防药物。